{{Rsnum
|rsid=1359645
|Chromosome=10
|position=108045657
|Orientation=plus
|GMAF=0.146
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 96.4 | 3.6 | 0.0
| HCB | 71.1 | 24.4 | 4.4
| JPT | 55.4 | 42.9 | 1.8
| YRI | 36.7 | 51.7 | 11.6
| ASW | 52.6 | 38.6 | 8.8
| CHB | 71.1 | 24.4 | 4.4
| CHD | 57.4 | 38.0 | 4.6
| GIH | 55.0 | 37.0 | 8.0
| LWK | 51.4 | 34.9 | 13.8
| MEX | 0.0 | 0.0 | 0.0
| MKK | 41.7 | 47.4 | 10.9
| TSI | 95.0 | 5.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1359645
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.08, combined P value= 1.62E-04. It is also associated with greater methotrexate clearance
|Drugs=methotrexate
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470201
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1359645
|overall_frequency_n=110
|overall_frequency_d=128
|overall_frequency=0.859375
|n_genomes=52
|n_genomes_annotated=0
|n_haplomes=95
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}